Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Formerly About Advanced Micro Devices -- Ignore unavailable to you. Want to Upgrade?

To: bentway who wrote (851288)	4/20/2015 11:51:26 PM
From: i-node	Read Replies (2) \| Respond to of 1579075

>> It looks to me like both of those are STILL very viable treatment options. "Very viable" would not be a correct statement for the typical breast cancer patient, I don't believe. Radical mastectomy is still used when the tumor is present in the chest wall or in the muscle. It was shown years ago that survival rates for other radical mastectomy were no better than simple lumpectomy. While high-dose chemo may still be used in unusual circumstances, it was determined in 1999 through randomized trials that high dose chemo kills more patients than traditional chemo methods.